Finally, a direct role for TGFβ in mediating AP2 binding to the BST2 promoter was confirmed in 3 independent primary breast tumor lines treated with the TGFβ inhibitor - SB 431542 prior to ChIP analysis (Figure 4C). Here, TGFB1 is linked to breast neoplasm.